Kynos Therapeutics
Edinburgh
About Kynos Therapeutics
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.8M
- Funding stage: M&A
- Last round: Seed (Apr 2022)
- Website: kynostx.com
- Phone: +441316517957
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kynos-therapeutics-12778 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.